Differences in Blood Brain Barrier of Children Hiv Art Cpe
Introduction
HIV affects an estimated 3.2 million children worldwide, and the majority of the 240,000 newly infected children are perinatally HIV (PHIV)-infected.1 The virus can enter the cardinal nervous system (CNS) within days after main infection, posing a major threat to neurodevelopment.2 Indeed, without combination antiretroviral therapy (cART), twenty%–50% of PHIV-infected children developed HIV-related encephalopathy.3 These children showed severe progressive neurological harm or arrested neurodevelopment, including failure to attain or loss of developmental milestones, impaired brain growth, and motor deficits.4 Initiation of cART, which combines multiple antiretroviral agents from at least two drug classes, has been shown to decrease the incidence of HIV encephalopathy to under 2%.3 Nonetheless, many PHIV-infected children nonetheless prove neurodevelopmental delay or neurocognitive impairment, which are thought to stand for milder forms of HIV encephalopathy.five
The pathogenesis of neurodevelopmental delay in PHIV-infected children is non yet fully understood. As the nervous system and immune system, which should control viral replication, are still developing in children,half-dozen and the clinical features of pediatric HIV encephalopathy differ from adult HIV-associated dementia (HAD), the underlying mechanisms of neurological pathogenesis may in part differ from that of adults.four,7 To place further the devastating effects of HIV infection in the developing CNS in children, recent investigations have focused on inflammation, coagulation, and vascular dysfunction, equally well as microstructural deviations assessed past multimodal neuroimaging. This review seeks to summarize current insights in the pathogenesis and evaluation of neurodevelopmental delay in PHIV-infected children and adolescents in the era of cART.
Clinical features
Neurodevelopmental delay spans motor, language, and cognitive domains, and affects HIV-infected children in both high-resource and depression-resource settings. However, reported rates and severity of developmental delay are highly variable, due to inconsistency amid tests and outcome measures, too as population differences in age, allowed condition, and cART regimens.8,ix Furthermore, PHIV-infected children are often exposed to multiple other chance factors for neurodevelopmental delay, both physical (eg, prematurity, depression birth weight or head circumference, stunting, wasting) and psychosocial (eg, low socioeconomic status, parental or caregiver unemployment, lower education level, or drug corruption), emphasizing the necessity of a well-matched control group for comparisons on HIV-related affliction.8,10
Impaired motor evolution is establish in upwards to 67% of PHIV-infected infants stable on cART when compared to either HIV-exposed but uninfected children, HIV-unexposed children, or national norms.11–14 The severity of these motor inadequacies varies from within normal range to more than two standard deviations below the population mean.12–fourteen Loss of motor function is less evident in older children, but subtle strength and fine-motor impairments take been reported in clinically stable schoolhouse-historic period PHIV-infected children, both cART-naïve and -experienced.xv,xvi
General knowledge is significantly affected from an early age onward. PHIV-infected infants, school-age children, and adolescents show poorer cognitive performance when compared to controls or national norms, with rates of severe damage (IQ <70 or scores more than two standard deviations below population mean) ranging from 16% to 46%.v,fifteen,17 Additionally, PHIV-infected children display variable deficits in all subdomains of cognitive functioning, ie, processing speed, attention, and working retentiveness, perceptual and visuospatial performance, and executive functioning,5,16,17 fifty-fifty when full general knowledge is within the normal range.18–20 Overall, processing speed, memory, and attention appear to be most severely afflicted.21
Language abatement is also seen in cART-treated PHIV-infected children of all ages. Both expressive and receptive language skills are poorer when compared to controls.15,22–25 Of annotation, this specific language disorder is independent of the presence of hearing deficits and lower general cognitive functioning as chance factors for language impairment.26
Impact
Few studies draw the consequences of impaired neurodevelopment on daily functioning of PHIV-infected children. Generally, a negative bear upon of HIV infection on schoolhouse performance is implied by poor school results, failing or repeating grades, and high rates of special education.5,24,27 However, school functioning is strongly influenced by many other factors, such as increased absence from schoolhouse due to illness, hearing loss, family circumstances, socioeconomic factors, and caregiver education or intelligence, making the directly effect of HIV difficult to determine.21,27 In that location is as well a strong association betwixt poorer neurocognitive functioning and depression, acquit disorders, and increased risk-taking beliefs in PHIV-infected adolescents, which may further negatively affect their health and academic performances.21,28
HIV-related risk factors
In utero exposure
Pediatric HIV studies ofttimes utilize HIV-exposed merely uninfected children every bit a control group. Yet, several studies prove that these children too take poorer cognitive operation when compared to HIV-unexposed children, suggesting that in utero exposure to HIV during pregnancy may already negatively affect subsequently neurodevelopment.23,24,29 It is known that HIV can invade the fetal CNS,30 although it is unclear how this relates to futurity HIV serostatus or cerebral injury. PHIV-infected children that developed encephalopathy afterward in life were found to have a smaller head circumference at birth compared to nonencephalopathic PHIV-infected children, also indicative of a prenatal disease process.4 Studies evaluating a potential protective consequence of in utero exposure to maternal cART employ report contrasting outcomes regarding neurodevelopment.12,31 Inquiry on the consequences of in utero exposure to HIV and cART is further complicated by the frequent presence of confounders, such as maternal substance abuse, prematurity, and low nascency weight.32,33
HIV disease severity
The poorest neurocognitive outcomes are seen in HIV-infected children with a history of higher disease severity, indicating a significant contribution of residual HIV-induced cerebral injury to neurodevelopmental delay at a later age. Indeed, having experienced a Centers for Affliction Control and Prevention class C event has been associated with lower scores in general cognition, processing speed, and verbal performance.5,24,34 This is in line with the finding of poorer outcomes in HIV-infected children with lower nadir CD4+ T-cell measurements and college zenith viral load, although this association is not consistently institute, possibly due to small written report groups.five,34,35 Younger age at HIV diagnosis is also associated with higher rates of neurodevelopmental filibuster,36,37 and encephalopathy was found to occur more frequently in PHIV-infected children when compared to adults after similar duration of HIV infection.4 Overall, these findings strongly suggest that perinatally infected children are more susceptible to CNS impairment caused by HIV infection than older children or adults.
In contrast to historical markers of HIV disease severity, HIV load and CD4+ T-cell count show less consistent correlations with neurocognitive operation,15,26,38 and some recent studies in children stable on cART did not find this correlation at all.5,24 While HIV load and CD4+ T-cell count are normally used as indicators of systemic HIV disease severity, to which the CNS may be exposed, they may not be a reliable indicator of HIV bear upon on the CNS. Systemic HIV load does not e'er represent cerebrospinal fluid (CSF) HIV load, which may exist a amend marker for cerebral HIV disease. However, studies accept failed to testify an association betwixt CSF viral load and neurocognitive functioning in the setting of adequate viral suppression with cART.39,40 This could be due to insensitivity of unremarkably used detection tests or CSF viral load being an imperfect proxy for brain-tissue HIV replication, but may as well indicate more prominent roles for other pathogenic mechanisms in chronic HIV-induced cognitive injury.40
Neuropathogenesis
Neurodevelopmental delay in pediatric HIV disease could be considered the mild terminate of the spectrum of HIV encephalopathy, with similar pathogenic mechanisms, simply express in severity by the improved handling strategies that have become bachelor over the last few decades.32 Several hypotheses concerning the neuropathogenesis of HIV exist, albeit largely based on histopathological studies in pre-cART adult populations.
Early HIV infection may lead to a degree of irreversible damage before the initiation of effective cART, which could account for some of the neurological deficits persisting over time.41 The contribution of this legacy outcome is supported past the predictive value of historical HIV disease markers. In a chronic state, HIV infection may continue to injure the CNS fifty-fifty afterwards HIV load suppression is achieved with cART. Firstly, the CNS is an anatomically distinct compartment in which HIV can escape therapy, allowing independent replication, genetic evolution, and continuing injury inside the CNS. Detectable intrathecal HIV load despite systemic viral suppression has indeed been reported in upwardly to 10% of both asymptomatic and neurologically symptomatic adults on cART, and discordance between plasma and CSF HIV genetic strains has been detected in adults and children on cART.39,42,43 Secondly, HIV infection – even with undetectable HIV load – may induce a chronic low-grade inflammatory state, consisting of persistent monocyte and macrophage activation, vascular endothelial activation, and a hypercoagulable country. Markers of inflammation and vascular dysfunction are indeed elevated in cohorts of cART-experienced children, correlating with poorer neurocognitive functioning.44,45 Furthermore, inflammation appears to be a meliorate predictor for neurocognitive impairment than HIV load or CD4+ T-prison cell measurements in adults.46 Finally, chronic exposure to cART may itself induce neurotoxicity, contrasting with the evidenced protective effects.47
HIV invasion of the CNS
To invade the CNS, HIV must penetrate the blood–brain barrier (BBB) (Figure 1A), which is composed of a layer of man brain microvascular endothelial cells (HBMECs) linked past tight junctions. These cells work in close communication with pericytes and astrocytes in regulating bidirectional traffic of cells and substances between the systemic circulation and the CNS.48 The about feasible mechanism by which HIV crosses the BBB is by transmigration of infected monocytes and to a lesser degree lymphocytes.49 HIV proteins, such equally gp120 and Tat, activate HBMECs, which then release inflammatory mediators, including TNFα and MCP-1, and limited specific adhesion molecules, such as ICAMs and VCAMs, facilitating invasion of infected monocytes into the brain.50,51 The permeability of the BBB is further increased by HIV-induced oxidative injury, functional damage of astrocytes and pericytes, and damage to tight junctions via upregulation of proteolytic MMPs, consequently allowing free HIV virions and viral proteins to pass through the BBB via transcellular and paracellular pathways.52–54 Productive infection of HBMECs is minimally evidenced, and thus unlikely to contribute significantly to HIV entry into the CNS.55
  | Figure 1 The furnishings of HIV on the cells of the primal nervous organization. |
HIV affects nearly CNS cell types, just primarily targets microglia and monocyte-derived macrophages in the perivascular infinite every bit the primary site of HIV infection and production in the encephalon (Figure 1B). These infected sites correspond with the highest concentrations of HIV in histopathological studies.56 HIV-infected and activated microglia and macrophages are major sources for viral products, chemokines, proinflammatory cytokines, and small-scale molecules, such as platelet-activating factor and quinolinic acid or derivatives thereof, that lead to farther immune activation and cerebral injury (Effigy 1C).55 Furthermore, fusion of these cells is thought to give rise to multinucleated behemothic cells, considered a hallmark of HIV encephalopathy.55
Astrocytes are highly abundant in the CNS, and regulate the environs of neurons, integrity of the BBB, and response to injury. Like to microglia, when activated past HIV, they proliferate (termed reactive astrocytosis) and release several inflammatory mediators.55 While HIV Dna has been detected within astrocytes, this may be the result of nonspecific – thus CD4 receptor-independent – uptake and release of the virus, and sustained infection leading to viral Dna integration and production of viral proteins remains hundred-to-one.56,57 The same is truthful for oligodendrocytes, which produce the myelin sheath that insulates neuronal axons.58 HIV tin can also touch on neural progenitor cells, which reside in select regions of the encephalon and play a disquisitional role in brain growth and repair afterward injury, every bit they are capable of forming new neurons, astrocytes, and oligodendrocytes.59 Exposure to HIV reduces proliferation of these cells, which may contribute to cognitive impairment, consistent with the finding of fewer hippocampal neural progenitor cells in adults with HAD.60
HIV-induced neuronal injury
Interestingly, neurons also lack the CD4 receptor necessary for HIV infection, and intraneuronal HIV is non consistently detected in adults or children with HIV-related CNS disease.56,61 However, the receptor-expression profile of neurons, which includes the HIV coreceptors CCR5 and CXCR4, renders them sensitive to injury acquired by viral proteins likewise as inflammatory mediators triggered by HIV infection.62
Direct exposure to structural viral proteins has been shown to be neurotoxic in vitro, although their exact contributions in vivo remain uncertain. Several viral proteins, including gp120, Tat, and Vpr, can directly induce neuronal apoptosis via chemokine receptors and intracellular pathways.62–65 Additionally, gp120 increases glutamate (Glu) release from microglia and impairs Glu uptake by astrocytes, leading to overstimulation of Northward-methyl-d-aspartate-receptors (Effigy 1D) and subsequent lethal Ca2+ influx (Figure 1E).66,67 Both Tat and gp120 tin further contribute to this mechanism by straight binding to North-methyl-d-aspartate-receptors.68,69 Local axonal degeneration may as well occur through gp120-induced caspase activation of CCR5 or CXCR4.70
Viral proteins also cause astrocyte dysfunction, which may lead to additional neuronal injury. Tat promotes expression of inducible nitric oxide synthase and production of nitric oxide by infected astrocytes, causing oxidative injury to neurons.71 Oligodendrocyte injury induced past gp120 or Tat could reduce myelination, which afterwards increases axonal vulnerability.72,73
Neuroinflammation
The CNS has a predominantly innate allowed response to injury, depending on activated glia and monocyte-derived cells, whereas in dissimilarity with the periphery, the role of T cells is much less clear.58 Monocyte- and macrophage-activation markers, such as plasma and CSF neopterin, soluble CD14 (sCD14) and plasma sCD163, are elevated in HIV-infected adults, correlating with presence or severity of neurocognitive impairment.2,46,74,75 In cognitively impaired HIV-infected adults, CSF sCD14 and sCD163 are likewise associated with CSF NFL, a marker of neurodegeneration, underpinning the role of persistent immune activation in HIV neuropathogenesis.76 Furthermore, cognitively impaired HIV-infected adults have college proportions of CD14+ CD16+ monocytes in the blood. This subpopulation is associated with chronic inflammation and a higher susceptibility to HIV infection and MCP-1 chemoattraction in comparison to their CD14+ CD16− counterparts.49,77,78 In PHIV-infected children, only neopterin and sCD14 levels have been evaluated, and were found to be systemically elevated.79,80 Potential associations with other measures of HIV-related cognitive injury take not notwithstanding been examined.
The ongoing immune activation leads to sustained release of cytokines and chemokines, consistent with increased levels of inflammatory mediators in the CSF of HIV-infected adults and children despite cART.46,81,82 Many HIV-induced proinflammatory cytokines, including TNFα, IL-1β, and IL-vi, amplify the effects of HIV through the induction of viral replication and further immune activation, as well equally beingness straight neurotoxic.55 In vitro, TNFα and IL-1β interfere with Glu uptake, contributing to excitotoxicity.83 Increased TNFα too causes oligodendrocyte expiry, which subsequently could impair myelination.83,84 IL-6 causes cytoplasmic vacuoles in neurons, resulting in neuronal dysfunction. Further recruitment of allowed cells and cytokine release is enhanced by diverse chemokines, such equally IL-viii, IP-ten, MIP-1α, MIP-1β, MCP-1, and RANTES.85,86
Contrastingly, the chemokines MCP-1, MIP-1α, RANTES, SDF-ane, and fractalkine can all in vitro protect neurons against apoptosis induced by gp120 or Tat, likely due to activation of pathways promoting neuronal survival.62,87,88 TNFα also prevents apoptosis of neurons expressing type ii TNF receptors, indicating that expression of specific receptors is crucial in the stardom between neurotoxic and neurotrophic effects.89 Every bit the net effect of many inflammatory mediators in vivo is unclear, their presence alone does not predict protection or injury. Indeed, while several inflammatory markers were detectable in the CSF of PHIV-infected children on cART, they did not correlate with systemic inflammation, HIV disease markers, or neurological symptoms.82 Even so, it does imply sustained encephalon inflammation in chronic HIV infection, warranting further research to place inflammatory mechanisms that may serve every bit predictors and possible therapeutic targets for cognitive injury in PHIV-infected children.
Prove of cerebral injury
Typical findings of HIV encephalopathy on conventional computed tomography or magnetic resonance imaging (MRI) sequences are cerebral atrophy, basal ganglia calcifications, and white-matter abnormalities. In the cART era, advanced imaging modalities to evaluate white-matter integrity, cognitive metabolites, and cerebral blood flow (CBF) show increasing show for microstructural injury in PHIV-infected children, fifty-fifty in the absenteeism of neurological symptoms or macrostructural lesions.90 These imaging modalities and the type of cognitive injury they capture are detailed in this section.
Information technology is important to interpret neuroimaging findings within the context of a developing brain, equally many physiological changes occur throughout childhood and adolescence. The majority of encephalon growth and myelin deposition occurs in infancy. In babyhood and adolescence, cognitive volume continues to increase at a slower charge per unit until adulthood, with a relative increase in white thing due to ongoing myelination and thinning of cortical gray thing as a effect of synaptic pruning. This maturation occurs in a posterior–inductive direction, corresponding to early development of visuomotor areas, while college-order cognitive functions utilizing prefrontal and parietal cortical regions mature in late babyhood and adolescence.half-dozen,21
Macrostructural injury
Cerebral atrophy, manifesting as cortical and subcortical volume reduction, sulcal widening, and ventriculomegaly (Effigy 2A), occurs in many clinically and immunologically stable PHIV-infected children and correlates with poorer cerebral functioning.91–93 Gray-matter atrophy is generally considered to represent loss of neuronal cells, but could also be a manifestation of impaired brain growth in HIV-infected children.90 In a longitudinal study, grey-matter volume increased over fourth dimension, suggesting that in the setting of adequate treatment, the physiological development of the CNS may at least partially compensate for neuronal loss in these children.91
 | Figure 2 HIV-induced cerebral injury. |
White-matter lesions (WML) are best seen on fluid-attenuated inversion-recovery MRI images as hyperintense areas diffusely spread throughout periventricular, deep, and juxtacortical white thing.91,92,94 WML are idea to represent sites of inflammation with glial proliferation and myelin injury (Figure 2B), while the presence of lesions in the well-perfused juxtacortical regions makes an exclusively vascular origin less likely.95,96 WML accept been detected in PHIV-infected infants initiated on cART within the 1st months of life, and remained stable over fourth dimension in some other study, suggesting a very early onset of pathogenesis.91,94 Notwithstanding, neither the presence, volume, nor distribution of WML clearly chronicle to neurodevelopmental outcomes in PHIV-infected children on cART.91,92,94
Microstructural injury
Fifty-fifty in the absence of structural imaging abnormalities, such as WML, white-affair harm measured by changes in diffusion values with diffusion-tensor imaging is apparent in stable PHIV-infected children.38,92 These changes are widespread throughout the white thing, indicating profuse myelin and axonal injury (Figure 2C). Reduced white-matter integrity was plant to correlate with higher HIV load, lower CD4+ T-cell nadir, and poorer cognitive functioning, and may therefore serve as a potentially early on marker of HIV-related developmental delay.38,92,97 Still, longitudinal studies studying such decay are lacking.
Several CSF biomarkers that are frequently reported in other degenerative and inflammatory CNS diseases, such as dementia and multiple sclerosis, may also be useful in the evaluation of HIV-related cerebral injury. Elevated CSF NFL, indicative of damage to myelinated axons in the white matter, has repeatedly been reported in HIV-infected adults, most prominently in clan with HAD or low CD4+ T-cell nadirs.74,98 College total or phosphorylated Tau levels, indicating cortical neurodegeneration, are seen most prominently in HIV-infected adults with HAD.98,99 Altered markers of amyloid processing accept also been reported, possibly respective with increased intraneuronal amyloid-β accumulation.74,98–100 Various other pediatric infectious, inflammatory, and demyelinating CNS disorders show distinctive patterns of biomarkers indicative of neuronal injury, including total Tau and NFL.101 Evaluation of these markers in PHIV-infected children may thus provide new insights into the underlying mechanisms of cerebral injury, and may help distinguish neurodegeneration from impaired brain growth due to HIV.
Magnetic resonance spectroscopy tin examine the metabolic integrity and density of neurons noninvasively through detection of changes in cerebral metabolites, even earlier structural changes occur or clinical symptoms go manifest.102 These metabolites are discussed here as a concentration ratio to creatine (Cre). Acute HIV infection in adults is associated with a rising in Glu (Glu:Cre) to potentially excitotoxic levels, accompanied by increases of choline (Cho:Cre) and myo-inositol (MI:Cre), representing increased membrane turnover and glial proliferation, respectively.2,74,103 Initiation of cART partially reverses some of these changes.103 Chronically HIV-infected adults and children prove persistent elevations in MI:Cre and Cho:Cre, suggestive of ongoing inflammation, while Glu:Cre and N-acetylaspartate (NAA:Cre) decrease, indicating neuronal dysfunction and degeneration.103–105 Contrastingly, decreased Cho:Cre in basal ganglia and frontal white matter has too been reported in immunologically stable PHIV-infected children.106 Equally the developing brain of children has a higher requirement for Cho, which is a component of cell membranes and myelin, this subtract may reflect impaired myelination and brain growth.107 In PHIV-infected children, an age-related increase in NAA – as normally seen in good for you controls – was lacking, over again suggesting dumb brain growth in HIV infection.106
Metabolite changes in HIV-infected adults correlate with the presence and severity of cerebral harm,108 and although pediatric studies relating cerebral metabolites to neurodevelopmental outcomes are limited, reports include associations between hippocampal Cho:Cre and spatial memory deficits and between overall NAA:Cho ratio and verbal IQ.104,106 Furthermore, while adult metabolite alterations correlate with several other indicators of HIV-related cerebral injury, such as cortical cloudburst, elevated NFL, and increased systemic or intrathecal inflammation, such relationships have non notwithstanding been studied in PHIV-infected children.ii,74,81,109
Cognitive claret flow and vascular illness
A college take a chance of cerebrovascular disease is well established in chronic HIV-infected adults, and is increasingly recognized in PHIV-infected children. Neuroimaging studies predating cART displayed calcifications of basal ganglia, the thalamus, and deep white matter in the bulk of children with CNS HIV disease.95 Histopathological studies correspondingly revealed vasculitis with calcifications within cerebral blood vessels.95,110 Other cerebrovascular abnormalities have been reported in PHIV-infected children, including ischemic stroke, aneurysms, and moyamoya malformations.111 However, their relation to neurodevelopmental outcomes is unclear.
Fifty-fifty with optimal cART, at that place are many probable contributors to vasculopathy in PHIV-infected children, including chronic low-grade inflammation, endothelial dysfunction, hypercoagulability, and disturbed glucose and lipid metabolism (Figure 2D). Indeed, HIV infection in children stable on therapy has been associated with college levels of high-sensitivity CRP, soluble adhesion molecules, and fibrinogen, as well as an unfavorable lipid contour.44,45,112 Elevations in P-selectin and fibrinogen were linked to poorer neurocognitive functioning.45 Additionally, findings of increased carotid intima-media thickness and decreased flow-mediated distension reveal structural and functional vascular changes, respectively. These measures also correlate with increased inflammation and an unfavorable lipid profile, and are most pronounced in children receiving a protease inhibitor.113 These findings allude to an early onset of vasculopathy accelerated by HIV-related inflammation and influenced by cART, rendering it a potential source of long-term comorbidity in PHIV-infected children surviving into adulthood. This underlines the relevance of further exploration of vascular health in this population.114
CBF has non been extensively researched in PHIV-infected children, as many of the neuroimaging modalities require exposure to radioactivity or contrast agents. A pocket-size positron-emission tomography study, predating cART, showed cortical hypometabolism in PHIV-infected children with and without encephalopathy, as well as basal ganglia hypermetabolism in those with encephalopathy.115 In HIV-infected adults, increased flow or metabolism is predominantly found in the basal ganglia and in early stages of infection, whereas reduced CBF is associated with chronic infection and localized in both cortical and subcortical structures.116,117 Flow alterations are more pronounced in cognitively impaired individuals, but also occur in neuroasymptomatic patients, suggesting CBF may testify useful as an early marking of cerebral injury in HIV.117,118 In theory, college flow may reveal areas of compensatory increased usage of brain reserve afterwards HIV injury, as suggested by altered task-based activation patterns on functional MRI.119,120 It may likewise reflect ongoing inflammation or vasodilatation due to increased release of nitrous oxide.116 Lower period may be related to loss of cells, although it is currently unclear whether catamenia changes are a cause or effect of volume changes.118 Furthermore, the relation between CBF and the vascular and coagulation effects of HIV is unclear. A promising opportunity to evaluate CBF in children is with the use of arterial spin labeling, a noninvasive MRI technique that yields results comparable to positron-emission tomography in HIV-infected adults,120 and was successfully used to assess resting-state period and the relation to cognitive operation in healthy children and children with sickle-jail cell anemia (Table 1).121
 | Table i Selected laboratory biomarkers in HIV neuropathogenesis |
Treatment effects
While cART has been shown to reduce HIV load and inflammatory markers effectively in CSF,39 it apparently does non fully forestall or reverse accrued CNS injury. Long-term furnishings of cART on cerebral health in HIV-infected children are unclear; most studies evaluating the effect of treatment initiation or optimization study on improvement of neurodevelopmental outcomes, but some do non.nine,15,22 While lack of improvement during treatment may reflect the severity of immunocompromise and injury prior to cART initiation, it also raises concern near cART neurotoxicity.
Timing of cART initiation
Neurodevelopmental delay may consequence from accrued CNS involvement, afterwards the virus has already entered and injured the CNS and prior to initiation of cART. Reported effects of early on versus deferred initiation of cART – ie, at study inclusion versus when criteria of immunosuppression or symptomatic affliction are met – are not consequent. Better neurodevelopmental scores were seen in infants who initiated cART within 12 weeks of life versus deferral to a hateful age of 31 weeks,thirteen in line with reports of better cognitive performance in schoolhouse-historic period children with adequate viral suppression early in life or cART initiation before an AIDS-defining issue.122,123 Another report found similar poor outcomes in both early on and deferred treatment groups, although the hateful age of initiating cART was significantly college, at 6 years.9 This suggests the window for benefit of early cART initiation in PHIV-infected children lies in infancy, and is in line with the theory that the younger age-group has an increased vulnerability to the neurological sequelae of HIV.
Challenges of cART in the CNS
While peripheral viral suppression with cART may reduce the amount of HIV entering the CNS, constructive treatment within the CNS compartment requires antiretroviral agents to penetrate the BBB. If HIV is exposed to subtherapeutic cART levels in the CNS, viral replication and mutation may occur despite acceptable systemic viral suppression, potentially leading to ongoing impairment and cART resistance.39,40 This is more often than not referred to as compartmentalization, and has been associated with the presence and severity of cerebral damage in adults.124 The CNS-penetration effectiveness score is oft used to categorize cART regimens based on CSF pharmacokinetics of the different antiretroviral agents, merely it has never been validated in children and was indeed not associated with IQ in 2 recent studies.122,123 Pediatric studies comparing plasma and CSF levels of antiretroviral agents are lacking. Additionally, it is unknown how well pharmacokinetics of cART in the CSF represent those in brain tissue.
The toxicity of antiretroviral agents has long been speculated to play a function in HIV-related neurocognitive impairments. Especially concerning are reports of children experiencing significant neurological turn down, despite immunological recovery after treatment initiation, and the occurrence of neuropsychiatric symptoms with use of the not-nucleoside reverse-transcriptase inhibitor efavirenz. In these reports, symptoms were reversible by treatment alteration or interruption.125–127 Little is known about the potential effects of cART on the different nervous system cell types and the exact mechanisms by which cART causes neurotoxicity. Several antiretroviral agents were indeed reported toxic to neurons in vitro, mostly causing dendrite pruning and altered responses to Glu.47 However, minimal jail cell death occurred, and but a few agents were toxic at concentrations typically achieved in the CSF of cART-treated HIV-infected adults. Additionally, nucleoside reverse-transcriptase inhibitors may interfere with mitochondrial Deoxyribonucleic acid γ-polymerase, resulting in mitochondrial dysfunction, although this has not been proven in children.128 Protease inhibitors accept been associated with disturbed lipid and glucose metabolism and increased carotid intima-media thickness in children, all risk factors for vascular disease.113 Such changes may touch the CNS and thereby influence neurodevelopment, peculiarly with the prolonged exposure to cART that occurs as PHIV-infected children survive into adulthood.
Adjuvant treatment options
Considering the increasing evidence for inflammatory influences in HIV neuropathogenesis, adjuvant handling with anti-inflammatory agents may reduce HIV-related cerebral injury. And then far, the drugs studied in adults have failed to elicit an effective response and thus have non been evaluated in children. Diverse nonpharmaceutical interventions, such every bit caregiver-preparation programs, may exist effective in improving neurocognitive functioning of PHIV-infected children, and should exist explored further.21
Conclusion and future directions
Neurodevelopmental delay affects a large proportion of PHIV-infected children, with deficits spanning multiple motor, language, and cognitive domains. The vulnerability of children with a young age at main HIV infection or a more severe disease history stresses the importance of prevention of mother-to-kid manual, equally well equally early on diagnosis and intervention. While cART is constructive in reducing cerebral injury by suppressing HIV load and subsequent inflammation, it plain does not fully protect against HIV-induced damage in the brain. Future studies should examine the underlying mechanisms of pediatric neurological HIV disease, focusing on age-related host allowed responses, pharmacokinetics, and toxicity of cART in the pediatric CNS. Neuroimaging of white-matter integrity, cerebral metabolites, and CBF are especially promising for the pediatric population, every bit they can discover subtle abnormalities before major structural damage and clinical symptoms occur or become apparent. When combined with laboratory evaluation of neurodegeneration and inflammation, this could significantly contribute to increasing our understanding of the neuropathogenesis of HIV infection in the pediatric brain, and peradventure aggrandize the window for optimal treatment or prevention. Equally PHIV-infected children on cART now survive into adulthood, longitudinal research is warranted to observe the long-term effects of HIV infection and cART exposure.
Disclosure
The authors report no conflicts of involvement in this work.
References
| ane. | Earth Wellness Organization. Global Update on the Health Sector Response to HIV, 2014. Geneva: WHO; 2014. |
| ii. | Valcour 5, Chalermchai T, Sailasuta N, et al. Cardinal nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012;206(2):275–282. |
| 3. | Patel K, Ming X, Williams PL, Robertson KR, Oleske JM, Seage GR. Affect of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS. 2009;23(14):1893–1901. |
| iv. | Tardieu M, Le Chenadec J, Persoz A, Meyer Fifty, Blanche S, Mayaux MJ. HIV-1-related encephalopathy in infants compared with children and adults. French Pediatric HIV Infection Written report and the SEROCO Grouping. Neurology. 2000;54(5):1089–1095. |
| 5. | Cohen S, Ter Stege JA, Geurtsen GJ, et al. Poorer cognitive performance in perinatally HIV-infected children versus healthy socioeconomically matched controls. Clin Infect Dis. 2015;60(seven):1111–1119. |
| 6. | Tau GZ, Peterson BS. Normal evolution of brain circuits. Neuropsychopharmacology. 2010;35(i):147–168. |
| 7. | Spudich Due south, González-Scarano F. HIV-1-related central nervous system illness: electric current issues in pathogenesis, diagnosis, and treatment. Common cold Bound Harb Perspect Med. 2012;two(6):a007120. |
| viii. | Van Rie A, Harrington PR, Dow A, Robertson G. Neurologic and neurodevelopmental manifestations of pediatric HIV/AIDS: a global perspective. Eur J Paediatr Neurol. 2007;11(1):1–9. |
| nine. | Puthanakit T, Ananworanich J, Vonthanak South, et al. Cognitive function and neurodevelopmental outcomes in HIV-infected children older than one year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study. Pediatr Infect Dis J. 2013;32(v):501–508. |
| 10. | Le Doaré Grand, Banal R, Newell ML. Neurodevelopment in children born to HIV-infected mothers by infection and handling status. Pediatrics. 2012;130(five):e1326–e1344. |
| 11. | Lindsey JC, Malee KM, Brouwers P, Hughes Doctor. Neurodevelopmental functioning in HIV-infected infants and immature children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy. Pediatrics. 2007;119(three):e681–e693. |
| 12. | Ferguson 1000, Jelsma J. The prevalence of motor delay amid HIV infected children living in Greatcoat Town, South Africa. Int J Rehabil Res. 2009;32(2):108–114. |
| 13. | Laughton B, Cornell One thousand, Grove D, et al. Early antiretroviral therapy improves neurodevelopmental outcomes in infants. AIDS. 2012;26(13):1685–1690. |
| 14. | Chase C, Ware J, Hittelman J, et al. Early cognitive and motor development amidst infants born to women infected with human immunodeficiency virus. Women and Infants Transmission Study Grouping. Pediatrics. 2000;106(2):E25. |
| 15. | Jeremy RJ, Kim South, Nozyce M, et al. Neuropsychological operation and viral load in stable antiretroviral therapy-experienced HIV-infected children. Pediatrics. 2005;115(2):380–387. |
| 16. | Ruel TD, Boivin MJ, Boal HE, et al. Neurocognitive and motor deficits in HIV-infected Ugandan children with loftier CD4 prison cell counts. Clin Infect Dis. 2012;54(7):1001–1009. |
| 17. | Lowick S, Sawry Southward, Meyers T. Neurodevelopmental filibuster among HIV-infected preschool children receiving antiretroviral therapy and healthy preschool children in Soweto, South Africa. Psychol Wellness Med. 2012;17(5):599–610. |
| 18. | Kandawasvika GQ, Kuona P, Chandiwana P, et al. The brunt and predictors of cognitive impairment among half dozen- to 8-year-one-time children infected and uninfected with HIV from Harare, Republic of zimbabwe: a cross-sectional study. Child Neuropsychol. 2015;21(1):106–120. |
| 19. | Fishkin PE. Cursory study: Relationship between HIV infection and WPPSI-R performance in preschool-age children. J Pediatr Psychol. 2000;25(5):347–351. |
| 20. | Koekkoek Southward, de Sonneville LM, Wolfs TF, Licht R, Geelen SP. Neurocognitive function profile in HIV-infected school-historic period children. Eur J Paediatr Neurol. 2008;12(4):290–297. |
| 21. | Laughton B, Cornell M, Boivin M, Van Rie A. Neurodevelopment in perinatally HIV-infected children: a concern for adolescence. J Int AIDS Soc. 2013;xvi(i):18603. |
| 22. | Whitehead North, Potterton J, Coovadia A. The neurodevelopment of HIV-infected infants on HAART compared to HIV-exposed but uninfected infants. AIDS Intendance. 2014;26(4):497–504. |
| 23. | Brahmbhatt H, Boivin M, Ssempijja V, et al. Neurodevelopmental benefits of antiretroviral therapy in Ugandan children aged 0–6 years with HIV. J Acquir Allowed Defic Syndr. 2014;67(3):316–322. |
| 24. | Brackis-Cott Due east, Kang Eastward, Dolezal C, Abrams EJ, Mellins CA. The impact of perinatal HIV infection on older school-anile children'south and adolescents' receptive language and word recognition skills. AIDS Patient Care STDS. 2009;23(6):415–421. |
| 25. | Van Rie A, Mupuala A, Dow A. Impact of the HIV/AIDS epidemic on the neurodevelopment of preschool-aged children in Kinshasa, Congo-kinshasa. Pediatrics. 2008;122(1):e123–e128. |
| 26. | Rice ML, Buchanan AL, Siberry GK, et al. Linguistic communication impairment in children perinatally infected with HIV compared to children who were HIV-exposed and uninfected. J Dev Behav Pediatr. 2012;33(2):112–123. |
| 27. | Souza Due east, Santos N, Valentini South, Silva Thou, Falbo A. Long-term follow-up outcomes of perinatally HIV-infected adolescents: infection control just schoolhouse failure. J Trop Pediatr. 2010;56(6):421–426. |
| 28. | Wood SM, Shah SS, Steenhoff AP, Rutstein RM. The touch on of AIDS diagnoses on long-term neurocognitive and psychiatric outcomes of surviving adolescents with perinatally caused HIV. AIDS. 2009; 23(14):1859–1865. |
| 29. | Kerr SJ, Puthanakit T, Vibol U, et al. Neurodevelopmental outcomes in HIV-exposed-uninfected children versus those not exposed to HIV. AIDS Care. 2014;26(eleven):1–nine. |
| xxx. | Lyman WD, Kress Y, Kure K, Rashbaum WK, Rubinstein A, Soeiro R. Detection of HIV in fetal primal nervous arrangement tissue. AIDS. 1990; 4(9):917–920. |
| 31. | Williams PL, Marino M, Malee K, Brogly S, Hughes Medico, Mofenson LM. Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants. Pediatrics. 2010;125(ii):e250–e260. |
| 32. | Crowell CS, Malee KM, Yogev R, Muller WJ. Neurologic affliction in HIV-infected children and the impact of combination antiretroviral therapy. Rev Med Virol. 2014;24(v):316–331. |
| 33. | Chiriboga CA, Fleishman South, Champion S, Gaye-Robinson L, Abrams EJ. Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active anti-retroviral therapy (HAART). J Pediatr. 2005;146(three):402–407. |
| 34. | Smith R, Chernoff Grand, Williams PL, et al. Affect of HIV severity on cognitive and adaptive functioning during childhood and boyhood. Pediatr Infect Dis J. 2012;31(6):592–598. |
| 35. | Nachman S, Chernoff M, Williams P, Hodge J, Heston J, Gadow KD. Man immunodeficiency virus disease severity, psychiatric symptoms, and functional outcomes in perinatally infected youth. Arch Pediatr Adolesc Med. 2012;166(vi):528–535. |
| 36. | Kandawasvika GQ, Ogundipe Due east, Gumbo FZ, Kurewa EN, Mapingure MP, Stray-Pedersen B. Neurodevelopmental impairment among infants born to mothers infected with human immunodeficiency virus and uninfected mothers from iii peri-urban main care clinics in Harare, Zimbabwe. Dev Med Child Neurol. 2011;53(eleven):1046–1052. |
| 37. | Smith R, Malee K, Charurat M, et al. Timing of perinatal human immunodeficiency virus type 1 infection and rate of neurodevelopment. Pediatr Infect Dis J. 2000;19(ix):862–871. |
| 38. | Hoare J, Fouche JP, Spottiswoode B, et al. A diffusion tensor imaging and neurocognitive report of HIV-positive children who are HAART-naïve "slow progressors". J Neurovirol. 2012;eighteen(3):205–212. |
| 39. | McCoig C, Castrejón MM, Castaño E, et al. Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy. J Pediatr. 2002;141(1):36–44. |
| 40. | Nightingale S, Winston A, Letendre S, et al. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014;13(eleven):1139–1151. |
| 41. | Chan P, Brew BJ. HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment. Curr HIV/AIDS Rep. 2014;11(3):317–324. |
| 42. | Edén A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202(12):1819–1825. |
| 43. | Canestri A, Lescure FX, Jaureguiberry Southward, et al. Discordance betwixt cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010;50(5):773–778. |
| 44. | Ross Ac, O'Riordan MA, Storer N, Dogra V, McComsey GA. Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children. Atherosclerosis. 2010;211(two):492–498. |
| 45. | Kapetanovic S, Leister E, Nichols Due south, et al. Relationships between markers of vascular dysfunction and neurodevelopmental outcomes in perinatally HIV-infected youth. AIDS. 2010;24(10):1481–1491. |
| 46. | Kamat A, Lyons J, Misra V. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr. 2012;60(iii):234–243. |
| 47. | Robertson Thousand, Liner J, Meeker RB. Antiretroviral neurotoxicity. J Neurovirol. 2012;18(5):388–399. |
| 48. | Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's affliction and other disorders. Nat Rev Neurosci. 2011; 12(12):723–738. |
| 49. | Hong S, Banks WA. Role of the allowed system in HIV-associated neuroinflammation and neurocognitive implications. Brain Behav Immun. 2015;45:1–12. |
| 50. | Chaudhuri A, Duan F, Morsey B, Persidsky Y, Kanmogne GD. HIV-one activates proinflammatory and interferon-inducible genes in human brain microvascular endothelial cells: putative mechanisms of claret-brain barrier dysfunction. J Cereb Claret Menstruum Metab. 2008;28(4):697–711. |
| 51. | Stins MF, Shen Y, Huang SH, Gilles F, Kalra VK, Kim KS. Gp120 activates children's brain endothelial cells via CD4. J Neurovirol. 2001;7(ii):125–134. |
| 52. | Muratori C, Mangino G, Affabris E, Federico M. Astrocytes contacting HIV-1-infected macrophages increase the release of CCL2 in response to the HIV-ane-dependent enhancement of membrane-associated TNFα in macrophages. Glia. 2010;58(sixteen):1893–1904. |
| 53. | Dohgu Southward, Banks WA. Encephalon pericytes increment the lipopolysaccharide-enhanced transcytosis of HIV-1 free virus across the in vitro blood-encephalon barrier: bear witness for cytokine-mediated pericyte-endothelial cell crosstalk. Fluids Barriers CNS. 2013;10(1):23. |
| 54. | Louboutin JP, Agrawal L, Reyes BA, Van Bockstaele EJ, Strayer DS. HIV-1 gp120-induced injury to the blood-brain bulwark: role of metalloproteinases 2 and 9 and relationship to oxidative stress. J Neuropathol Exp Neurol. 2010;69(8):801–816. |
| 55. | Rao VR, Ruiz AP, Prasad VR. Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND). AIDS Res Ther. 2014;11(ane):13. |
| 56. | Trillo-Pazos G, Diamanturos A, Rislove L, et al. Detection of HIV-1 DNA in microglia/macrophages, astrocytes and neurons isolated from brain tissue with HIV-1 encephalitis by laser capture microdissection. Brain Pathol. 2003;13(ane):144–154. |
| 57. | Sabri F, Tresoldi E, Di Stefano M, et al. Nonproductive human immunodeficiency virus blazon 1 infection of human being fetal astrocytes: independence from CD4 and major chemokine receptors. Virology. 1999;264(two):370–384. |
| 58. | Kramer-Hämmerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R. Cells of the central nervous system equally targets and reservoirs of the human immunodeficiency virus. Virus Res. 2005;111(ii):194–213. |
| 59. | Schwartz L, Major EO. Neural progenitors and HIV-1-associated key nervous system disease in adults and children. Curr HIV Res. 2006;iv(3):319–327. |
| 60. | Krathwohl Doc, Kaiser JL. HIV-one promotes quiescence in man neural progenitor cells. J Infect Dis. 2004;190(2):216–226. |
| 61. | An SF, Groves M, Gray F, Scaravilli F. Early on entry and widespread cellular involvement of HIV-1 DNA in brains of HIV-1 positive asymptomatic individuals. J Neuropathol Exp Neurol. 1999;58(11):1156–1162. |
| 62. | Meucci O, Fatatis A, Simen AA, Bushell TJ, Gray Pow, Miller RJ. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci U Southward A. 1998;95(24):14500–14505. |
| 63. | Bachis A, Biggio F, Major EO, Mocchetti I. M- and T-tropic HIVs promote apoptosis in rat neurons. J Neuroimmune Pharmacol. 2009; 4(1):150–160. |
| 64. | Eugenin EA, King JE, Nath A, et al. HIV-tat induces formation of an LRP-PSD-95-NMDAR-nNOS circuitous that promotes apoptosis in neurons and astrocytes. Proc Natl Acad Sci U S A. 2007;104(9):3438–3443. |
| 65. | Jones GJ, Barsby NL, Cohen EA, et al. HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci. 2007;27(14):3703–3711. |
| 66. | Huang Y, Zhao Fifty, Jia B, et al. Glutaminase dysregulation in HIV-1-infected homo microglia mediates neurotoxicity: relevant to HIV-1-associated neurocognitive disorders. J Neurosci. 2011;31(42):15195–15204. |
| 67. | Wang Z, Pekarskaya O, Bencheikh M, et al. Reduced expression of glutamate transporter EAAT2 and dumb glutamate transport in human being primary astrocytes exposed to HIV-i or gp120. Virology. 2003;312(1):sixty–73. |
| 68. | Cocky RL, Mulholland PJ, Nath A, Harris BR, Prendergast MA. The man immunodeficiency virus blazon-1 transcription factor Tat produces elevations in intracellular Ca2+ that crave function of an Due north-methyl-d-aspartate receptor polyamine-sensitive site. Brain Res. 2004;995(1):39–45. |
| 69. | Gemignani A, Paudice P, Pittaluga A, Raiteri M. The HIV-i coat protein gp120 and some of its fragments potently actuate native cerebral NMDA receptors mediating neuropeptide release. Eur J Neurosci. 2000;12(8):2839–2846. |
| 70. | Melli Thousand, Keswani SC, Fischer A, Chen W, Höke A. Spatially distinct and functionally independent mechanisms of axonal degeneration in a model of HIV-associated sensory neuropathy. Brain. 2006;129(Pt 5):1330–1338. |
| 71. | Liu X, Jana Yard, Dasgupta Due south, et al. Human being immunodeficiency virus blazon 1 (HIV-i) tat induces nitric-oxide synthase in human astroglia. J Biol Chem. 2002;277(42):39312–39319. |
| 72. | Bernardo A, Agresti C, Levi Thousand. HIV-gp120 affects the functional activity of oligodendrocytes and their susceptibility to complement. J Neurosci Res. 1997;fifty(vi):946–957. |
| 73. | Hauser KF, Hahn YK, Adjan VV, et al. HIV-1 Tat and morphine have interactive effects on oligodendrocyte survival and morphology. Glia. 2009;57(two):194–206. |
| 74. | Peluso MJ, Meyerhoff DJ, Price RW, et al. Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during chief HIV infection. J Infect Dis. 2013;207(11):1703–1712. |
| 75. | Burdo Th, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC. Elevated sCD163 in plasma but not cerebrospinal fluid is a mark of neurocognitive damage in HIV infection. AIDS. 2013;27(9):1387–1395. |
| 76. | McGuire J, Gill A, Douglas South, Kolson D. Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders. J Neurovirol. 2015;21(4):439–448. |
| 77. | Fischer-Smith T, Croul S, Sverstiuk AE, et al. CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular aggregating and reservoir of HIV infection. J Neurovirol. 2001;vii(6):528–541. |
| 78. | Williams DW, Calderon TM, Lopez L, et al. Mechanisms of HIV entry into the CNS: increased sensitivity of HIV infected CD14+CD16+ monocytes to CCL2 and key roles of CCR2, JAM-A, and ALCAM in diapedesis. PLoS One. 2013;viii(7):e69270. |
| 79. | Syed SS, Balluz RS, Kabagambe EK, et al. Cess of biomarkers of cardiovascular take a chance amid HIV-1 infected adolescents: role of soluble vascular prison cell adhesion molecule (sVCAM) as an early indicator of endothelial inflammation. AIDS Res Hum Retroviruses. 2013;29(3):493–500. |
| eighty. | Sainz T, Diaz L, Navarro ML, et al. Cardiovascular biomarkers in vertically HIV-infected children without metabolic abnormalities. Atherosclerosis. 2014;233(2):410–414. |
| 81. | Anderson AM, Harezlak J, Bharti A, et al. Plasma and cerebrospinal fluid biomarkers predict cerebral injury in HIV-infected individuals on stable combination antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;69(1):29–35. |
| 82. | McCoig C, Castrejón MM, Saavedra-Lozano J, et al. Cerebrospinal fluid and plasma concentrations of proinflammatory mediators in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2004;23(2):114–118. |
| 83. | Ye L, Huang Y, Zhao Fifty, et al. IL-1β and TNF-α induce neurotoxicity through glutamate production: a potential part for neuronal glutaminase. J Neurochem. 2013;125(6):897–908. |
| 84. | Wilt SG, Milward Due east, Zhou JM, et al. In vitro show for a dual function of tumor necrosis factor-α in human immunodeficiency virus type ane encephalopathy. Ann Neurol. 1995;37(3):381–394. |
| 85. | Yang B, Akhter S, Chaudhuri A, Kanmogne GD. HIV-1 gp120 induces cytokine expression, leukocyte adhesion, and transmigration across the claret-brain barrier: modulatory effects of STAT1 signaling. Microvasc Res. 2009;77(2):212–219. |
| 86. | González-Scarano F, Martín-García J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005;5(one):69–81. |
| 87. | Kaul One thousand, Lipton SA. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci U Due south A. 1999;96(fourteen):8212–8216. |
| 88. | Eugenin EA, D'Aversa TG, Lopez L, Calderon TM, Berman JW. MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J Neurochem. 2003;85(5):1299–1311. |
| 89. | Marchetti Fifty, Klein M, Schlett K, Pfizenmaier G, Eisel ULM. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced past N-methyl-D-aspartate receptor activation: essential role of a TNF receptor ii-mediated phosphatidylinositol 3-kinase-dependent NF-κB pathway. J Biol Chem. 2004;279(31):32869–32881. |
| xc. | Hoare J, Ransford GL, Phillips North, Amos T, Donald Thou, Stein DJ. Systematic review of neuroimaging studies in vertically transmitted HIV positive children and adolescents. Metab Brain Dis. 2014;29(2):221–229. |
| 91. | van Arnhem LA, Bunders MJ, Scherpbier HJ, et al. Neurologic abnormalities in HIV-1 infected children in the era of combination antiretroviral therapy. PLoS Ane. 2013;viii(v):e64398. |
| 92. | Cohen S, Caan 1000, Mutsaerts H, et al. Cerebral injury in perinatally HIV-infected children compared to matched healthy controls. Neurology. In printing 2015. |
| 93. | Martin SC, Wolters PL, Toledo-Tamula MA, Zeichner SL, Hazra R, Civitello L. Cognitive functioning in school-aged children with vertically acquired HIV infection being treated with highly active antiretroviral therapy (HAART). Dev Neuropsychol. 2006;30(2):633–657. |
| 94. | Ackermann C, Andronikou S, Laughton B, et al. White thing point abnormalities in children with suspected HIV-related neurologic illness on early combination antiretroviral therapy. Pediatr Infect Dis J. 2014;33(8):e207–e212. |
| 95. | Kure K, Llena JF, Lyman WD, et al. Human immunodeficiency virus-1 infection of the nervous arrangement: an autopsy written report of 268 adult, pediatric, and fetal brains. Hum Pathol. 1991;22(7):700–710. |
| 96. | Kim KW, MacFall JR, Payne ME. Classification of white matter lesions on magnetic resonance imaging in elderly persons. Biol Psychiatry. 2008;64(4):273–280. |
| 97. | Hoare J, Fouche JP, Phillips N, et al. Clinical associations of white thing damage in cART-treated HIV-positive children in South Africa. J Neurovirol. 2015;21(2):120–128. |
| 98. | Peterson J, Gisslen M, Zetterberg H, et al. Cerebrospinal fluid (CSF) neuronal biomarkers beyond the spectrum of HIV infection: hierarchy of injury and detection. PLoS One. 2014;nine(12):e116081. |
| 99. | Calcagno A, Atzori C, Romito A, et al. Cerebrospinal fluid biomarkers in patients with plasma HIV RNA beneath xx copies/mL. J Int AIDS Soc. 2014;17(4 Suppl 3):19719. |
| 100. | Achim CL, Adame A, Dumaop W, Everall IP, Masliah E. Increased aggregating of intraneuronal amyloid β in HIV-infected patients. J Neuroimmune Pharmacol. 2009;four(ii):190–199. |
| 101. | Shahim P, Darin N, Andreasson U, et al. Cerebrospinal fluid brain injury biomarkers in children: a multicenter study. Pediatr Neurol. 2013;49(i):31–39. e2. |
| 102. | Masters MC, Ances BM. Office of neuroimaging in HIV-associated neurocognitive disorders. Semin Neurol. 2014;34(i):89–102. |
| 103. | Immature Air-conditioning, Yiannoutsos CT, Hegde M, et al. Cerebral metabolite changes prior to and afterward antiretroviral therapy in primary HIV infection. Neurology. 2014;83(xviii):1592–1600. |
| 104. | Gabis L, Belman A, Huang Westward, Milazzo Grand, Nachman S. Clinical and imaging study of human immunodeficiency virus-1-infected youth receiving highly active antiretroviral therapy: airplane pilot study using magnetic resonance spectroscopy. J Child Neurol. 2006;21(vi):486–490. |
| 105. | Prado PT, Escorsi-Rosset Due south, Cervi MC, Santos Air conditioning. Paradigm evaluation of HIV encephalopathy: a multimodal approach using quantitative MR techniques. Neuroradiology. 2011;53(11):899–908. |
| 106. | Keller MA, Venkatraman TN, Thomas A, et al. Altered neurometabolite development in HIV-infected children: correlation with neuropsychological tests. Neurology. 2004;62(10):1810–1817. |
| 107. | Rae CD. A guide to the metabolic pathways and function of metabolites observed in man brain oneH magnetic resonance spectra. Neurochem Res. 2014;39(1):1–36. |
| 108. | Mohamed MA, Barker Atomic number 82, Skolasky RL, et al. Encephalon metabolism and cognitive impairment in HIV infection: a 3-T magnetic resonance spectroscopy study. Magn Reson Imaging. 2010;28(9):1251–1257. |
| 109. | Cohen RA, Harezlak J, Gongvatana A, et al. Cerebral metabolite abnormalities in man immunodeficiency virus are associated with cortical and subcortical volumes. J Neurovirol. 2010;16(6):435–444. |
| 110. | Shah SS, Zimmerman RA, Rorke LB, Vezina LG. Cerebrovascular complications of HIV in children. Am J Neuroradiol. 1996;17(x):1913–1917. |
| 111. | Wilmshurst JM, Donald KA, Eley B. Update on the primal developments of the neurologic complications in children infected with HIV. Curr Opin HIV AIDS. 2014;ix(vi):533–538. |
| 112. | Miller TL, Borkowsky W, Dimeglio LA, et al. Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med. 2012;13(five):264–275. |
| 113. | Charakida M, Donald AE, Light-green H, et al. Early structural and functional changes of the vasculature in HIV-infected children: impact of illness and antiretroviral therapy. Circulation. 2005;112(ane):103–109. |
| 114. | Idris N, Grobbee D, Burgner D, et al. Cardiovascular manifestations of HIV infection in children. Eur J Prev Cardiol. 2015;22(xi):1452–1461. |
| 115. | Depas M, Chiron C, Tardieu M, et al. Functional encephalon imaging in HIV-one-infected children built-in to seropositive mothers. J Nucl Med. 1995;36(12):2169–2174. |
| 116. | Tracey I, Hamberg LM, Guimaraes AR, et al. Increased cerebral claret volume in HIV-positive patients detected by functional MRI. Neurology. 1998;l(6):1821–1826. |
| 117. | Ances BM, Sisti D, Vaida F, et al. Resting cerebral blood catamenia: a potential biomarker of the effects of HIV in the brain. Neurology. 2009;73(9):702–708. |
| 118. | Ances BM, Roc AC, Wang J, et al. Caudate claret flow and volume are reduced in HIV+ neurocognitively dumb patients. Neurology. 2006;66(6):862–866. |
| 119. | Melrose RJ, Tinaz South, Castelo JM, Courtney MG, Stern CE. Compromised fronto-striatal performance in HIV: an fMRI investigation of semantic issue sequencing. Behav Brain Res. 2008;188(2):337–347. |
| 120. | Towgood KJ, Pitkanen K, Kulasegaram R, et al. Regional cerebral blood flow and FDG uptake in asymptomatic HIV-1 men. Hum Encephalon Mapp. 2013;34(10):2484–2493. |
| 121. | Kilroy E, Liu CY, Yan Fifty, et al. Relationships between cognitive blood flow and IQ in typically developing children and adolescents. J Cogn Sci (Seoul). 2011;12(2):151–170. |
| 122. | Lazarus JR, Rutstein RM, Lowenthal ED. Handling initiation factors and cerebral outcome in youth with perinatally acquired HIV infection. HIV Med. 2015;16(vi):355–361. |
| 123. | Crowell CS, Huo Y, Tassiopoulos M, et al. Early viral suppression improves neurocognitive outcomes in HIV-infected children. AIDS. 2015;29(iii):295–304. |
| 124. | Svicher V, Ceccherini-Silberstein F, Antinori A, Aquaro S, Perno CF. Understanding HIV compartments and reservoirs. Curr HIV/AIDS Rep. 2014;xi(2):186–194. |
| 125. | Tamula MA, Wolters PL, Walsek C, Zeichner S, Civitello L. Cognitive turn down with immunologic and virologic stability in four children with homo immunodeficiency virus disease. Pediatrics. 2003;112(3):679–684. |
| 126. | Toll RW, Spudich S. Antiretroviral therapy and cardinal nervous arrangement HIV blazon 1 infection. J Infect Dis. 2008;197(Suppl iii):S294–S306. |
| 127. | Church building JA, Mitchell WG, Gonzalez-Gomez I, et al. Mitochondrial Deoxyribonucleic acid depletion, well-nigh-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy. J Pediatr. 2001;138(5):748–751. |
| 128. | Alimenti A, Forbes JC, Oberlander TF, et al. A prospective controlled study of neurodevelopment in HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy. Pediatrics. 2006;118(four):e1139–e1145. |
Source: https://www.dovepress.com/hiv-delay-in-pediatric-hivaids-current-perspectives-peer-reviewed-fulltext-article-NBHIV
0 Response to "Differences in Blood Brain Barrier of Children Hiv Art Cpe"
Postar um comentário